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Abstract
Background: Randomized controlled trials are the gold standard for evaluating therapy; however, controversy
exists regarding the applicability of such results to daily practice, as patients are often pre-selected and may not
reflect real-world clinical settings. We studied the eligibility criteria for 3102 “real-life” patients with stable coronary
artery disease (SCAD) according to the ISCHEMIA (International Study of Comparative Health Effectiveness with
Medical and Invasive Approaches) trial exclusion criteria. The aim of our analysis was to estimate the percentage of
real-life patients who would have met the exclusion criteria for the ISCHEMIA trial.
Methods: We analyzed 3102 patients with SCAD referred to the Silesian Center for Heart Disease who underwent
both coronary angiography and stent implantation between January 2006 and December 2011. The patients were
divided into two groups. Group A was composed of patients with SCAD who would have been excluded from the
ongoing ISCHEMIA trial, whereas group B represented the remaining patients.
Results: A total of 1900 (61.3 %) patients met at least one of the exclusion criteria. The most frequent exclusion
criterion noted was revascularization within the previous 12 months (938 patients; 49.4 %), followed by
unacceptable level of angina symptoms (532 patients; 28 %), low ejection fraction (467 patients; 24.6 %), and acute
coronary syndrome within the previous 2 months (456 patients; 24 %). Patients from our cohort who would have
been excluded from the ISCHEMIA trial were older, had more comorbidities, and experienced worse long-term
outcomes.
Conclusions: The ISCHEMIA trial exclusion criteria ruled out the majority of the patients with SCAD undergoing
percutaneous coronary intervention in “real life”. Our cohort of patients who would have been excluded from the
ISCHEMIA trial had more comorbidities and experienced significantly worse long-term outcomes than patients who
did not meet the ISCHEMIA trial exclusion criteria.
Trial registration: ClinicalTrials.gov NCT01471522.
Keywords: ISCHEMIA trial, Revascularization versus optimal medical treatment, Stable coronary artery disease
* Correspondence: jaroswasilewski@gmail.com
Medical University of Silesia, School of Medicine with the Division of
Dentistry, 3rd Department of Cardiology, Silesian Center for Heart Diseases,
Marii Skłodowskiej-Curie Street 9, 41-800 Zabrze, Poland
TRIALS
© 2015 Wasilewski et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wasilewski et al. Trials  (2015) 16:411 
DOI 10.1186/s13063-015-0934-4
Background
Stable coronary artery disease (SCAD) remains one of
the most common indications for referral to a cardiac
catheterization laboratory [1]. Primary treatment goals
in patients with SCAD include the prevention of acute
coronary syndrome and the relief of ischemia. Percutan-
eous coronary intervention and coronary artery bypass
grafting are established methods of improving cardiac
symptoms [2, 3].
The benefits of revascularization remain unclear. The
COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) trial demonstrated
no difference in mortality between patients with SCAD
who were treated invasively and those who treated using
optimal medical therapy [4]. Although the COURAGE
trial was composed of a wider spectrum of patients than
previous studies [5–11], there were concerns regarding
its design, related to potential selection biases [12]. A
meta-analysis by Boden et al. [4] demonstrated that, in
patients with SCAD, percutaneous coronary intervention
did not offer any benefit in terms of mortality, incidence
of myocardial infarction or need for subsequent revascu-
larization over optimal medical therapy; however, a more
recent meta-analysis by Windecker et al. [13] provided
evidence regarding improved survival with the use of
new-generation drug-eluting stents as opposed to bal-
loon angioplasty, bare metal stents or early-generation
drug-eluting stents.
Numerous trials have compared optimal medical ther-
apy with revascularization for periods of up to 30 days
[14–17], but all of them included cohorts selected via
randomization. Therefore, the results of those studies may
not be representative for the entire population of patients
undergoing percutaneous coronary intervention in real
life, particularly among subgroups of patients with a high
baseline cardiovascular risk who are excluded from most
randomized trials [17]. In a study that included low risk
patients with SCAD, the use of an invasive strategy wors-
ened the prognosis of myocardial infarction, stroke and
cardiovascular death, as did the use of repetitive revascu-
larization [18] and other techniques, suggesting modest
benefits [19–21]. Therefore, selection bias and risk burden
are crucial in establishing the suitability of invasive revas-
cularization in a broad spectrum of patients with SCAD.
The purpose of the ongoing ISCHEMIA (International
Study of Comparative Health Effectiveness with Medical
and Invasive Approaches) trial is to determine the best
management strategy for high-risk patients with stable
ischemic heart disease and proven ischemia, using differ-
ent diagnostic modalities. The primary aim of the IS-
CHEMIA trial is to test the hypothesis that the use of
an invasive strategy, followed by revascularization plus
optimal medical therapy, in patients with either moder-
ate or severe ischemia inducible on stress imaging, is
superior to a conservative strategy (optimal medical
therapy only) [22].
In this analysis, we studied the eligibility criteria of
3102 consecutive patients with SCAD who underwent
stent implantation, according to the exclusion criteria of
the ISCHEMIA trial, to determine what percentage of
real-world patients would be excluded from the ISCHE-
MIA trial. In addition, we characterized both the risk
profiles and the long-term outcomes of patients who did
not fulfill the exclusion criteria of the ISCHEMIA trial.
Methods
We analyzed a cohort of 3502 patients with SCAD who
were referred to the Silesian Center for Heart Disease
(Zabrze, Poland) and underwent both coronary angiog-
raphy and stent implantation between January 2006 and
December 2011.
We screened all patients who underwent coronary
angiography but were discharged with diagnosis other
than SCAD (ICD10 I25.0 or I25.2) [23]. The screening
was performed to identify patients admitted because of
angina symptoms but discharged with another diagnosis
(for example, cardiogenic shock) owing to in-hospital
complications. Data regarding patients’ clinical and
demographic characteristics, as well as their symptoms
on admission, were taken from an electronic database
containing data from structured medical charts. This
database has been used to store information regarding
patients’ medical histories at our institution since 2006.
Patients’ echocardiography, angiography and laboratory
test results were collected from the medical history data-
base. All patients admitted to our center signed consent
forms for data collection and processing and provided
phone contact as part of our admission procedure. Pa-
tients who did not consent to phone contact were ex-
cluded from this analysis. All patients fulfilled the
ISCHEMIA inclusion age criterion. The youngest analyzed
patient was 29 years old. Out of a group of 3502 patients,
400 patients were excluded from further analysis due to
incomplete data. A further study was conducted on a
group of 3102 patients with complete clinical data. The
study was approved by the ethics committee at the re-
gional medical chamber (Ethics Committee of Silesian
Medical Chamber, Katowice; Resolution number 34/2011
from 21 November 2011).
Follow-up data
Information regarding survival was based on patients’
Polish National Health Fund insurance status, which
may be verified electronically, as this national health
insurance is mandatory for all Polish citizens; patients
who were insured were considered to be alive. We
attempted to contact the relatives of any uninsured
patients, as well as the relevant local registry office,
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to obtain patients’ dates of death. Complete follow-up
data were available for 3086 (99.5 %) patients. The
median follow-up duration was 3.5 years. During the
observation period, 366 deaths were reported.
ISCHEMIA trial exclusion criteria
We analyzed the exclusion criteria using an ISCHEMIA
study protocol available online. The exclusion criteria
that we applied to the cohort are given in Fig. 1. Re-
garding the ISCHEMIA trial protocol, we did not note
any restrictions pertaining to patients who underwent a
previous valve replacement procedure. Therefore, we
considered an implanted heart valve to be an exclusion
criterion. The patients were divided into two groups.
Group A was composed of patients with SCAD who
would have been excluded from the ongoing ISCHEMIA
Fig. 1 Scheme of the study. Owing to retrospective type of analysis or insufficient data, the following criteria were not applicable: finding of
non-obstructive coronary artery disease, unsuitable coronary anatomy, pregnancy, patients with an estimated glomerular filtration rate of 30–59
who were likely to have significant unprotected left main stenosis, inability to comply with the ISCHEMIA protocol, very dissatisfied with medical
treatment, ischemic stroke within 6-months, history of non-compliance
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trial, whereas group B represented the remaining patients
who did not meet the ISCHEMIA exclusion criteria.
Statistical analysis
Continuous variables are presented as medians and inter-
quartile ranges. Categorical variables are presented as per-
centages. Continuous variables were compared using
either the t test or the Mann–Whitney U test, where ap-
propriate. Long-term prognoses were analyzed in both
groups using the Kaplan–Meier method, with log-rank
testing. All reported values of P are two-sided. The ana-
lyses were performed using Statistica, version 7.1 (StatSoft,
Inc., Tulsa, OK, USA), and Number Crunching Statistical
Systems, version 8 (NCSS; Kaysville, UT, USA).
Results
A total of 1900 (61.3 %) patients met at least one of the
exclusion criteria pertaining to the ISCHEMIA trial. The
most frequent exclusion criterion noted was revasculariza-
tion within the previous 12 months (938 patients; 49.4 %),
followed by unacceptable level of angina symptoms (532
patients; 28 %), low ejection fraction (467 patients; 24.6 %)
and acute coronary syndrome within the previous 2
months (456 patients; 24 %) (Fig. 1). A total of 802 (44.2
%) patients fulfilled more than one exclusion criterion.
The basic clinical characteristics of our cohort and the pa-
tients who met the exclusion criteria (group A), as well as
those of the remaining patients (group B), are listed in
Table 1. The patients who would have been excluded from
the ISCHEMIA study (group A) were older and had more
comorbidities, including myocardial infarction, previous
revascularization, diabetes, hypertension, heart failure, and
lower ejection fraction. These patients exhibited lower
hemoglobin levels (median 8.5 mmol versus 8.8 mmol, P
< 0.001) and hematocrits (median 41 % versus 42 %, p <
0.001), as well as lower estimated glomerular filtration
rates (median 84.0 ml/min/ 1.73 m2) versus 85.2 ml/min/
1.73 m2), P < 0.001) and higher creatinine levels (median
80.1 mmol/l vs. 77.7 mmol/l, P < 0.001) (Table 2). Group
A also exhibited a higher incidence of multivessel disease
(median 22.1 % versus 18.1 %, P = 0.01) (Table 3).
Additionally, the patients who met at least one of the ex-
clusion criteria pertaining to the ISCHEMIA trial had
worse long-term prognosis. During the follow-up period,
79 (6.6 %) patients in group B and 287 (15.1 %) patients in
group A, respectively, died. The mortality for the whole
analyzed group was 11.8 % (366 patients). Figure 2 shows
the Kaplan–Meier survival curves for cohorts who met
the exclusion criteria for the ISCHEMIA trial (group A),
as well as the data pertaining to the patients who would
have been eligible for the ISCHEMIA trial (group B).
Multivariate analysis of independent predictors of mortal-
ity in the analyzed group was presented in additiona ma-
terial (Additional file 1).
Discussion
In patients with SCAD, invasive treatment has been shown
to improve coronary symptoms compared with optimal
medical therapy alone; however, revascularization does not
offer any benefits in terms of death, myocardial infarction
or the need for subsequent revascularization [2–5].
Randomized controlled trials are the gold standard for
evaluating therapeutic efficacy; however, there is contro-
versy regarding the applicability of such findings to daily
practice. For example, it has been reported that as many
as 50 % of patients with myocardial infarction in the real
world might not be represented in randomized clinical
trials [24].
Both selection bias and risk burden are crucial in
determining the utility of revascularization in a hetero-
geneous group of patients with symptomatic SCAD. We
aimed to answer the question regarding how much of
our population with SCAD who underwent stent im-
plantation would have been excluded from the ISCHE-
MIA trial.
Based on our analysis, it should be noted that the results
of the ISCHEMIA trial may not be extrapolated to a wide
spectrum of patients, including subgroups of patients with
moderately impaired left ventricular function, heart fail-
ure, previous myocardial infarction and revascularization,
or severe angina symptoms. We want to stress the import-
ance of registries as valuable data sources. Registries
include data from all-comers, or the real-world popula-
tion; therefore, an assessment of the potential benefits of
different treatment modalities on a wider spectrum of pa-
tients is possible. However, there is no better way to estab-
lish proper management strategies for high-risk patients
than randomized controlled trials.
Out of 938 patients excluded owing to prior revasculari-
zation within 12 months, 789 underwent percutaneous
coronary intervention as part of a staged revascularization
after myocardial infarction. The second part of revascular-
ization is performed after the acute phase of myocardial
infarction and symptoms are consistent with symptoms
reported by patients suffering from SCAD only; percutan-
eous coronary intervention is performed only if the lesion
is significant. Therefore, we are convinced that analysis of
this subgroup is essential.
Study limitations
It is important to note that the results of this study repre-
sent only a single-center experience. Despite the fact that a
structured medical interview regarding patients’ detailed
medical histories and symptoms on admission has been
mandatory for an attending physicians since 2006, this was
a retrospective observational study with several intrinsic
limitations. Moreover, as we are a cardiology referral center
in Poland, a larger proportion of high-risk patients may
have been cared for at our center than in other centers.
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Table 1 Baseline clinical characteristics, expressed as percentages or as medians and interquartile ranges
Variable All patients Group A Group B P
(Patients who met ISCHEMIA
exclusion criteria)
(Patients who did not meet
ISCHEMIA exclusion criteria)
(A vs. B)
n = 3102 n = 1900 n = 1202
Median age, years 64 (57–71) 64 (57–72) 64 (57–70) 0.11
Men 2187 (70.5) 1354 (71.3) 833 (69.3) 0.26
Previous myocardial infarction 1786 (57.6) 1335 (70.3) 451 (37.5) <0.001
Previous percutaneous coronary intervention 1451 (46.9) 1166 (61.4) 285 (23.7) <0.001
Previous coronary artery bypass graft 407 (13.1) 253 (13.3) 154 (12.8) 0.7
Diabetes 1118 (36.1) 785 (41.3) 333 (27.8) <0.001
Diabetes treatment Diet only 238 (7.7) 1176 (9.3) 62 (5.2) <0.001
Insulin 433 (14.0) 284 (14.9) 149 (12.4)
Oral drugs 447 (14.4) 325 (17.1) 670 (55.7)
Hypertension 2217 (71.5) 1301 (68.5) 916 (76.2) <0.001
Hypercholesterolemia 1752 (56.5) 1082 (57) 670 (55.7) 0.53
Current smoker 1140 (36.9) 719 (37.8) 421 (35) 0.09
Past smoker 331 (10.7) 187 (9.8) 144 (12) 0.09
Obesity 1035 (33.4) 626 (33) 409 (34) 0.56
Family history of premature myocardial infarction
(<55 years)
256 (9.3) 155 (8.3) 131 (10.9) 0.01
Systolic blood pressure (mmHg) 130 (120–140) 130 (120–140) 130 (120–140) <0.001
Diastolic blood pressure (mmHg) 80 (70–85) 80 (70–85) 80 (70–85) 0.03
Heart rate (min−1) 70 (63–76) 70 (63–77) 70 (64–76) 0.32
Heart failure 568 (18.3) 496 (26.1) 72 (6) <0.001
Ejection fraction (%) 48 (40–55) 45 (35–50) 50 (46–55) <0.001
Mitral valve regurgitation, severe 75 (2.5) 75 (4.1) 0 <0.001
Mitral valve stenosis, severe 4 (0.1) 4 (0.2) 0
Aortic stenosis, severe 24 (0.8) 24 (1.3) 0
Aortic regurgitation, severe 7 (0.2) 7 (0.4) 0 <0.001
Aortic valve insufficiency, combined 5 (0.2) 5 (0.3) 0
Bicuspid aortic valve 6 (0.2) 6 (0.3) 0
Tricuspid regurgitation, severe 26 (0.9) 26 (1.4) 0 <0.001
Table 2 Laboratory data, expressed as medians and interquartile ranges
Variable All patients Group A Group B P
(Patients who met ISCHEMIA
exclusion criteria)
(Patients who did not meet
ISCHEMIA exclusion criteria)
(A vs. B)
n = 3102 n = 1900 n = 1202
Red blood cell count (106/µL) 4.5 (4.2–4.8) 4.4 (4.1–4.8) 4.6 (4.3–4.9) <0.001
Hemoglobin (mmol/l) 8.6 (8–9.2) 8.5 (7.8–9) 8.8 (8.2–9.4) <0.001
Hematocrit (%) 41 (38–45) 41 (38–45) 42 (39–45) <0.001
White blood cells (103/mm3) 7.2 (6.1–8.4) 7.1 (6–8.4) 7.2 (6.1–8.5) 0.49
Platelets (103/mm3) 200 (163–240) 199 (163–241) 200 (164–235) 0.68
Creatinine (mmol/l) 79.2 (67.2–93.5) 80.1 (68.5–96) 77.7 (66–90) <0.001
Estimated glomerular filtration rate
(ml/min 1.73 m2))
83.3 (67.8–99.7) 82 (62.6–99.3) 85.2 (68.3–100.1) <0.001
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However, the application of the current guidelines and
treatment methods is also higher than average in Poland.
Conclusions
Our single-center comprehensive analysis has raised con-
cerns regarding the fact that the ISCHEMIA trial does not
represent a real-world heterogeneous group of patients with
SCAD. The majority of our patients who met exclusion cri-
teria as defined in the ISCHEMIA trial had undergone prior
percutaneous coronary intervention or coronary artery
bypass graft within the previous 12 months, or had a low
ejection fraction, and therefore had a worse long-term
prognosis. New randomized trials may be necessary, to de-
termine the benefits of revascularization among high-risk
patients with SCAD.
Additional file
Additional file 1: Multivariate analysis of independent predictors of
mortality in the analyzed group. To identify predictors of long-term
outcome, Cox regression models were utilized to evaluate the association
between clinical laboratory electrocardiographic and angiographic
variables and mortality. The stepwise selection of model building was
used, with P = 0.1 for a confounder to stay in the model. (PDF 276 kb)
Table 3 Angiographic characteristics and procedural complications, expressed as percentages or as median and interquartile ranges
Variable All
patients
Group A Group B P
(Patients who met ISCHEMIA
exclusion criteria)
(Patients who did not meet
ISCHEMIA exclusion criteria)
(A vs. B)
n = 3102 n = 1900 n = 1202
Angiographic characteristics
Multivessel disease 636 (20.5) 419 (22.1) 217 (18.1) 0.01
Significant stenosis; left main coronary artery 157 (5.1) 129 (6.8) 28 (2.3) <0.001
Significant stenosis – left anterior descending or diagonal 1781 (57.4) 1092 (57.5) 689 (57.3) 0.94
Significant stenosis – circumflex or obtuse marginal 1620 (52.2) 579 (48.2) 1041 (54.8) <0.001
Significant stenosis – right coronary artery 1746 (56.3) 1045 (55) 701 (58.3) 0.07
Number of vessels, percutaneous coronary intervention 1 (1–1) 1 (1–1) 1 (1–1) 0.005
Number of stents 1 (1–2) 1 (1–2) 1 (1–2) 0.005
Implanted stent bare metal stent 1785 (57.5) 1087 (57.2) 698 (58.1)
drug-eluting stent 1211 (39) 743 (39.1) 468 (38.9) 0.57
bare metal stent and drug-eluting stent 106 (3.5) 70 (3.7) 36 (3)
Complications
Myocardial infarction 40 (1.3) 27 (1.4) 13 (1.1) 0.51
Stroke or transient ischemia attack 10 (0.3) 9 (0.5) 1 (0.1) 0.1
Bleeding 52 (1.7) 29 (1.5) 23 (1.9) 0.47
Blood transfusion 30 (1.0) 22 (1.2) 8 (0.7) 0.19
Dissection 159 (5.1) 108 (5.7) 51 (4.2) 0.08
Repeat of percutaneous transluminal coronary angioplasty 9 (0.3) 5 (0.3) 4 (0.3) 0.74
Urgent coronary artery bypass graft 2 (0.1) 1 (0.1) 1 (0.1) 1.0
Sudden cardiac arrest 30 (1) 16 (0.8) 14 (1.2) 0.45
Mortality 366 (11.9) 287 (15.1) 79 (6.6) <0.001
Fig. 2 Kaplan–Meier survival plots of patients meeting the exclusion
criteria for the ISCHEMIA trial (group A) and patients who would
have been eligible for the ISCHEMIA trial (group B)
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